NeuroVive Pharmaceutical AB Year End Report January - December 2019
STOCKHOLM, Feb. 19, 2020 /PRNewswire/ -- Important events in 2019 KL1333 * NeuroVive enrolls first subject in its European KL1333 phase Ia/b clinical study * NeuroVive initiates second part of its ongoing KL1333 Phase Ia/b clinical study * NeuroVive compl...
NeuroVive Announces Settlement in Dispute With CicloMulsion AG
LUND, Sweden, Dec. 16, 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announced today that it has fully and finally settled the dispute with CicloMulsion AG regarding certain pharmaceutical technology. In 2004, NeuroVive entered into a License Agreement wi...
NeuroVive Pharmaceutical AB Interim Report January - September 2019
STOCKHOLM, Nov. 20, 2019 /PRNewswire/ -- Important events July - September * NeuroVive initiates second part of its ongoing KL1333 Phase Ia/b clinical study * NeuroSTAT receives Fast Track designation from the US Food and Drug Administration. Financial information third quarter (July-Septem...
NeuroVive Pharmaceutical AB Interim Report January - June 2019
STOCKHOLM, Aug. 21, 2019 /PRNewswire/ -- Important events April - June * The US Food and Drug Administration, FDA, approves NeuroVive's IND (Investigational New Drug) application, enabling clinical studies in the US with the company's drug candidate NeuroSTAT. * The Supreme Court delivers it...
NeuroVive's IND for Clinical Development of NeuroSTAT Approved by FDA
LUND, Sweden, May 10, 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) today announced that the US Food and Drug Administration, FDA, has approved NeuroVive's IND (Investigational New Drug) application, enabling clinical studies in the US with the company's ...
NeuroVive Pharmaceutical AB Publishes 2018 Annual Report
LUND, Sweden, 25 March 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq
Stockholm: NVP, OTCQX: NEVPF) today announced that the English version of the
Annual report for 2018 is now available on the company's website
www.neurovive.com
NeuroVive Receives Vinnova Funding to Support Development of NV354, a Novel Treatment for Genetic Mitochondrial Disorders
LUND, Sweden, Nov. 15, 2018 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announced today that the company has been awardedSEK 1.5 million as a first tranche of total SEK 5 million in funding from Vinnova,Sweden's innovation agency, and the Swelife call, for i...
NeuroVive Reports First NeuroSTAT Clinical Efficacy Signal in TBI
LUND, Sweden, Oct. 4, 2018 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced the successful completion of biomarker analyses of samples from its clinical study in severe traumatic brain injury patients (the CHIC study) using the company's investigat...
NeuroVive Receives Positive FDA Feedback on its NeuroSTAT TBI Development Plan
LUND, Sweden, Sept. 6 2018 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) today announced positive U.S. Food and Drug Administration (FDA) feedback on its NeuroSTAT clinical development plan for the treatment of moderate to severe Traumatic Brain Injury (TBI) a...
NeuroVive's NVP015 Program Will be Accelerated Through Award of Major Research Grant to Children's Hospital of Philadelphia
LUND, Sweden, Aug. 28, 2018 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) today announced that scientists at the company's research partner the Children's Hospital ofPhiladelphia (CHOP) have received a three-year grant (W81XWH-17-PRMRP-TTDA), in total of$4,090...
NeuroVive Pharmaceutical AB Interim Report January - June 2018
STOCKHOLM, Aug. 21, 2018 /PRNewswire/ -- Important events January-June 2018 * NeuroVive out-licenses targeted LHON therapy to BridgeBio Pharma's new subsidiary Fortify Therapeutics. The agreement has a total potential value of approximately$60 million USD including any royalties. * NeuroVive ...
NeuroVive Out-licenses Targeted LHON Therapy to BridgeBio Pharma's New Subsidiary Fortify Therapeutics
LUND, Sweden and PALO ALTO, Calif., June 19, 2018 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) and BridgeBio Pharma today jointly announced that BridgeBio has entered into an exclusive licensing agreement for a subset of succinate prodrug chemistry under Neuro...
NeuroVive Pharmaceutical AB Interim Report January - March 2018
STOCKHOLM, May 22, 2018 /PRNewswire/ -- Successful rights issue Business operations Important events January – March 2018 * NeuroVive decided to conduct a rights issue for the continued development of the company's drug projects following shareholder approval at an Extraordinary General Meeti...
NeuroVive Initiates Collaboration With Leading US TBI Research Organization
LUND, Sweden, May 2, 2018 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced a partnership with TRACK-TBI, a network of US-based world-leading TBI clinicians and researchers. The purpose of the network that NeuroVive now will be a part of intends to ...
Amendment: Resolutions From Annual General Meeting in NeuroVive Pharmaceutical AB (publ)
LUND, Sweden, 27 April 2018 /PRNewswire/ --NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF)("NeuroVive") today on 27 April 2018 held its Annual General Meeting (AGM). A summary of the resolutions follows. All resolutions were passed with the required majority. Approval of prof...
NeuroVive's Partner Yungjin Pharm Completes KL1333 Phase I Study Recruitment
LUND, Sweden, April 17, 2018 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) and Yungjin Pharm Corporation Ltd (South Korea Stock Market, KRX 003520) today announced that the last visit of the last healthy volunteer in the clinical phase I single ascending dose ...
NeuroVive Decides on a Rights Issue for Continued Drug Development
LUND, Sweden, Feb. 15, 2018 /PRNewswire/ -- NeuroVive Pharmaceutical AB (publ) (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announces that the Board of Directors of NeuroVive Pharmaceutical AB (publ) ("NeuroVive" or "the Company") on15 February 2018 resolved, subject to approval by the Extraordinary Gen...
NeuroVive Reports Breakthrough in Mitochondrial Myopathy Project
LUND, Sweden, Jan. 29, 2018 /PRNewswire/ -- NeuroVive Pharmaceutical AB(Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced a breakthrough in the company's project NVP025 for developing treatment of mitochondrial myopathy. In an experimental study carried out in collaboration with researchers at...
NeuroVive to Present at the 10th Annual Biotech Showcase Conference
LUND, Sweden, Jan. 3, 2018 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), today announced that the company is scheduled to present the 10th Annual Biotech Showcase Conference, held8-10 January 2018 in San Francisco, USA. The presentation will highlight the com...
NeuroVive Reports Promising Progress in its Clinical Project for Genetic Mitochondrial Diseases, KL1333
LUND, Sweden, Dec. 11, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB(Nasdaq Stockholm: NVP, OTCQX: NEVPF) and Yungjin Pharm today announced that the phase I clinical study in Korea within the companies' joint project KL1333, an investigational treatment for genetic mitochondrial disorders, inc...
